Post by Hot Christian Stocks on May 8, 2012 12:46:33 GMT -5
IMDS - Imaging Diagnostic Systems, Inc.
About Imaging Diagnostic Systems, Inc.
The CTLM system is a near infrared laser based breast imaging system intended to provide the physician with physiological and clinical information non-invasively and without the use of ionizing radiation. The patient is positioned in the prone position comfortably on the scanning bed. The laser beam sweeps 360 degrees starting at the chest wall moving forward until the entire breast is scanned. The CTLM features 3-dimensional and Multi-planar views that display the distribution of blood supply within the vasculature structures of the breast. This information when interpreted by a trained physician can be useful in diagnostic determination. The CTLM system has received the following certification and licenses enabling international sales; European CE marking, CMDCAS Canadian License, China SFDA, UL, ISO13485:2003 and FDA export certification.
Imaging Diagnostic Systems Inc.
5307 NW 35th Terrace
Fort Lauderdale, Florida 33309
Tel: (1) 954.581.9800
Fax: (1) 954.581.0555
Website: www.imds.com
www.otcmarkets.com/stock/IMDS/quote
www.sec.gov/Archives/edgar/data/790652/000079065212000016/0000790652-12-000016-index.htm
Current Management
Linda Grable - Chairman of The Board, CEO & Director
Mrs. Grable is a Founder and significant shareholder of Imaging Diagnostic Systems, Inc. During her tenure, Mrs. Grable was pivotal in raising over 52 million dollars in equity funding for the research and development of the CTLM system.
A graduate of Ohio State University with a BA degree in Journalism and Marketing, she had over 30 years of experience in financial negotiations for both medical and real estate development businesses. In addition, she had over 20 years of executive experience in the medical device industry, for both sales and marketing in the U.S. and foreign countries.
Allan Schwartz - Executive Vice-President, CFO and Co-Founder - Director
Mr. Schwartz joined IDSI in 1994. Mr. Schwartz is the Chief Financial Officer and Executive Vice-President. He has a broad range of management, marketing, engineering, and business development experience. Mr. Schwartz is the developer of the Chronometric Trading System for analyzing stock market trends using neural networks. He also pre-engineered homes for export to Belize, Central America for S.E Enterprises of Miami, Florida. In 1991 he formed Tron Industries, Inc. for the development of low-voltage and self-contained battery powered portable neon products. He is a graduate of C.W. Post College of Long Island University with a B.S. in Business Administration.
Deborah O'Brien - Senior Vice-President
Deborah O'Brien was appointed Senior Vice President on September 15, 2003. Ms. O'Brien joined IDSI in 1995. She has held the positions of Director of Investor Relations, Vice President of Corporate Communications and most recently, since September 2001, Vice President of Business Development. Her responsibilities included developing and executing a strategic corporate communications campaign, managing internal communications and IDSI public relations. Ms. O'Brien developed and established a program of consumer and industry awareness of the CTLM System via a media outreach which targeted industry publications, national network television, radio, nationally-circulated publications and high traffic internet sites.
Ms. O'Brien is responsible for IDSI's FDA process including clinical data collection, preparation, filings, and interface with the FDA. Prior to joining IDSI, she worked for seven years in the financial arena, managing investor accounts, and in the medical device industry, marketing medical equipment. Ms. O'Brien began her career in the mortgage loan industry as an account executive with Citibank.
David Schmidt – Director
On August 1, 2011, Mr. Schmidt was appointed by our Board of Directors to serve on the Board. Mr. Schmidt has served since 2008 as an independent consultant advising companies in the chemicals and materials, healthcare, and alternate energy industries regarding strategic marketing and execution services. From 2004 until 2008, Mr. Schmidt served as the Manager of Commercial Excellence and the Strategic Marketing and Business Development Manager at Honeywell International, Inc., Morristown, NJ. From 2000 until 2003, Mr. Schmidt served as a Senior Director and Chief Operations Officer of Plasmion Corporation, Inc., Hoboken, NJ. Mr. Schmidt has also served in management and officer positions at Film Specialties, Inc., Hillsborough, NJ, from 1993 until 2000; at Hydromer, Inc., Whitehouse, NJ, an invasive medical device specialty coatings company from 1989 until 1992; and at ROI Group, Inc., Parsippany, NJ, from 1986 until 1988. Mr. Schmidt earned his bachelor of science in business and economics from Lehigh University.
The CT Laser Mammography is an innovative device that can image the human breast to detect angiogenesis which may be an early indicator for cancer.
The Computed Tomography Laser Mammography (CTLM) Model 1020 is an imaging device that is intended to provide the physician with physiological and clinical information, obtained non-invasively and without the use of ionizing radiation. The CTLM Model 1020 produces 3-dimensional, coronal, sagittal, and axial cross-sectional images that display the distribution of hemoglobin within the internal structure of the breast. When interpreted by a trained physician, those images provide information that can be useful in diagnostic determination. The CTLM is a dedicated breast imaging system intended to be used as an adjunct to conventional breast screening methods.
The CTLM is unique because it uses no x-radiation—only laser light—to create a 3D image. Unlike x-ray mammography, the CTLM never compresses or even touches the breast making the entire exam easy and painless.
IDSI will be applying for FDA approval to sell and market the device in the USA. In the meantime we are marketing the product in many other countries where approvals have already been granted.
Our "intended use" will support our premise that CT Laser Mammography is designed to be an adjunct to conventional breast imaging methods to provide additional information that may be useful in making a diagnosis.
In the future, we believe laser optical breast scanning may be a primary method of diagnostic imaging response to therapy and other applications.
About Imaging Diagnostic Systems, Inc.
The CTLM system is a near infrared laser based breast imaging system intended to provide the physician with physiological and clinical information non-invasively and without the use of ionizing radiation. The patient is positioned in the prone position comfortably on the scanning bed. The laser beam sweeps 360 degrees starting at the chest wall moving forward until the entire breast is scanned. The CTLM features 3-dimensional and Multi-planar views that display the distribution of blood supply within the vasculature structures of the breast. This information when interpreted by a trained physician can be useful in diagnostic determination. The CTLM system has received the following certification and licenses enabling international sales; European CE marking, CMDCAS Canadian License, China SFDA, UL, ISO13485:2003 and FDA export certification.
Imaging Diagnostic Systems Inc.
5307 NW 35th Terrace
Fort Lauderdale, Florida 33309
Tel: (1) 954.581.9800
Fax: (1) 954.581.0555
Website: www.imds.com
www.otcmarkets.com/stock/IMDS/quote
www.sec.gov/Archives/edgar/data/790652/000079065212000016/0000790652-12-000016-index.htm
Current Management
Linda Grable - Chairman of The Board, CEO & Director
Mrs. Grable is a Founder and significant shareholder of Imaging Diagnostic Systems, Inc. During her tenure, Mrs. Grable was pivotal in raising over 52 million dollars in equity funding for the research and development of the CTLM system.
A graduate of Ohio State University with a BA degree in Journalism and Marketing, she had over 30 years of experience in financial negotiations for both medical and real estate development businesses. In addition, she had over 20 years of executive experience in the medical device industry, for both sales and marketing in the U.S. and foreign countries.
Allan Schwartz - Executive Vice-President, CFO and Co-Founder - Director
Mr. Schwartz joined IDSI in 1994. Mr. Schwartz is the Chief Financial Officer and Executive Vice-President. He has a broad range of management, marketing, engineering, and business development experience. Mr. Schwartz is the developer of the Chronometric Trading System for analyzing stock market trends using neural networks. He also pre-engineered homes for export to Belize, Central America for S.E Enterprises of Miami, Florida. In 1991 he formed Tron Industries, Inc. for the development of low-voltage and self-contained battery powered portable neon products. He is a graduate of C.W. Post College of Long Island University with a B.S. in Business Administration.
Deborah O'Brien - Senior Vice-President
Deborah O'Brien was appointed Senior Vice President on September 15, 2003. Ms. O'Brien joined IDSI in 1995. She has held the positions of Director of Investor Relations, Vice President of Corporate Communications and most recently, since September 2001, Vice President of Business Development. Her responsibilities included developing and executing a strategic corporate communications campaign, managing internal communications and IDSI public relations. Ms. O'Brien developed and established a program of consumer and industry awareness of the CTLM System via a media outreach which targeted industry publications, national network television, radio, nationally-circulated publications and high traffic internet sites.
Ms. O'Brien is responsible for IDSI's FDA process including clinical data collection, preparation, filings, and interface with the FDA. Prior to joining IDSI, she worked for seven years in the financial arena, managing investor accounts, and in the medical device industry, marketing medical equipment. Ms. O'Brien began her career in the mortgage loan industry as an account executive with Citibank.
David Schmidt – Director
On August 1, 2011, Mr. Schmidt was appointed by our Board of Directors to serve on the Board. Mr. Schmidt has served since 2008 as an independent consultant advising companies in the chemicals and materials, healthcare, and alternate energy industries regarding strategic marketing and execution services. From 2004 until 2008, Mr. Schmidt served as the Manager of Commercial Excellence and the Strategic Marketing and Business Development Manager at Honeywell International, Inc., Morristown, NJ. From 2000 until 2003, Mr. Schmidt served as a Senior Director and Chief Operations Officer of Plasmion Corporation, Inc., Hoboken, NJ. Mr. Schmidt has also served in management and officer positions at Film Specialties, Inc., Hillsborough, NJ, from 1993 until 2000; at Hydromer, Inc., Whitehouse, NJ, an invasive medical device specialty coatings company from 1989 until 1992; and at ROI Group, Inc., Parsippany, NJ, from 1986 until 1988. Mr. Schmidt earned his bachelor of science in business and economics from Lehigh University.
The CT Laser Mammography is an innovative device that can image the human breast to detect angiogenesis which may be an early indicator for cancer.
The Computed Tomography Laser Mammography (CTLM) Model 1020 is an imaging device that is intended to provide the physician with physiological and clinical information, obtained non-invasively and without the use of ionizing radiation. The CTLM Model 1020 produces 3-dimensional, coronal, sagittal, and axial cross-sectional images that display the distribution of hemoglobin within the internal structure of the breast. When interpreted by a trained physician, those images provide information that can be useful in diagnostic determination. The CTLM is a dedicated breast imaging system intended to be used as an adjunct to conventional breast screening methods.
The CTLM is unique because it uses no x-radiation—only laser light—to create a 3D image. Unlike x-ray mammography, the CTLM never compresses or even touches the breast making the entire exam easy and painless.
IDSI will be applying for FDA approval to sell and market the device in the USA. In the meantime we are marketing the product in many other countries where approvals have already been granted.
Our "intended use" will support our premise that CT Laser Mammography is designed to be an adjunct to conventional breast imaging methods to provide additional information that may be useful in making a diagnosis.
In the future, we believe laser optical breast scanning may be a primary method of diagnostic imaging response to therapy and other applications.